Karin Säljö

Dr. Karin Säljö

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2007 in The Journal of Physiology
Verified
Journal Article
Closed access
SRSara Roos
Sara Roos
NJNina Jansson
Nina Jansson
IPIsabelle Palmberg
Isabelle Palmberg
KSKarin Säljö
Karin Säljö
TPTheresa Powell
Theresa Powell
TJThomas Jansson
Thomas Jansson

6 June 2007 in The Journal of Physiology
Verified
Journal Article
Closed access
AEAnette Ericsson
Anette Ericsson
KSKarin Säljö
Karin Säljö
ESEleonor Sjöstrand
Eleonor Sjöstrand
NJNina Jansson
Nina Jansson
PPPuttur D. Prasad
Puttur D. Prasad
TJThomas Jansson
Thomas Jansson

1 March 2020 in Bioprinting
Verified
Journal Article
Closed access
KSKarin Säljö
Karin Säljö
LOLinnéa Stridh Orrhult
Linnéa Stridh Orrhult
PAPeter Apelgren
Peter Apelgren
KMKajsa Markstedt
Kajsa Markstedt
LKLars Kölby
Lars Kölby
PGPaul Gatenholm
Paul Gatenholm

1 July 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ABAngela Barone
Angela Barone
KSKarin Säljö
Karin Säljö
JBJohn Benktander
John Benktander
MBMaria Blomqvist
Maria Blomqvist
JMJan-Eric Månsson
Jan-Eric Månsson
Susann TenebergSusann Teneberg
Susann Teneberg
Cell surface glycoconjugates are used as markers for undifferentiated pluripotent stem cells. Here, antibody binding and mass spectrometry characterization of acid glycosphingolipids isolated from a large number (1 × 109 cells) of human embryonic stem cell (hESC) lines allowed identification of several novel acid glycosphingolipids, like the gangliosides sialyl-lactotetraosylceramide and sialyl-globotetraosylceramide, and the sulfated glycosphingolipids sulfatide, sulf-lactosylceramide, and sulf-globopentaosylceramide. A high cell surface expression of sialyl-lactotetra on hESC and human induced pluripotent stem cells (hiPSC) was demonstrated by flow cytometry, immunohistochemistry, and electron microscopy, whereas sulfated glycosphingolipids were only found in intracellular compartments. Immunohistochemistry showed distinct cell surface anti-sialyl-lactotetra staining on all seven hESC lines and three hiPSC lines analyzed, whereas no staining of hESC-derived hepatocyte-like or cardiomyocyte-like cells was obtained. Upon differentiation of hiPSC into hepatocyte-like cells, the sialyl-lactotetra epitope was rapidly down-regulated and not detectable after 14 days. These findings identify sialyl-lactotetra as a promising marker of undifferentiated human pluripotent stem cells.

21 June 2016 in Glycoconjugate Journal
Verified
Journal Article
Open access
PDF file
MBMichael E. Breimer
Michael E. Breimer
KSKarin Säljö
Karin Säljö
ABAngela Barone
Angela Barone
Susann TenebergSusann Teneberg
Susann Teneberg
The application of human stem cell technology offers theoretically a great potential to treat various human diseases. However, to achieve this goal a large number of scientific issues remain to be solved. Cell surface carbohydrate antigens are involved in a number of biomedical phenomena that are important in clinical applications of stem cells, such as cell differentiation and immune reactivity. Due to their cell surface localization, carbohydrate epitopes are ideally suited for characterization of human pluripotent stem cells. Amongst the most commonly used markers to identify human pluripotent stem cells are the globo-series glycosphingolipids SSEA-3 and SSEA-4. However, our knowledge regarding human pluripotent stem cell glycosphingolipid expression was until recently mainly based on immunological assays of intact cells due to the very limited amounts of cell material available. In recent years the knowledge regarding glycosphingolipids in human embryonic stem cells has been extended by biochemical studies, which is the focus of this review. In addition, the distribution of the human pluripotent stem cell glycosphingolipids in human tissues, and glycosphingolipid changes during human stem cell differentiation, are discussed.

27 December 2021 in Adipocyte
Verified
Journal Article
Open access
KSKarin Säljö
Karin Säljö
PAPeter Apelgren
Peter Apelgren
LOLinnea Stridh Orrhult
Linnea Stridh Orrhult
SLSusann Li
Susann Li
MAMatteo Amoroso
Matteo Amoroso
LKLars Kölby
Lars Kölby
Three-dimensional (3D)-bioprinted lipoaspirate-derived adipose tissue (LAT) is a potential alternative to lipo-injection for correcting soft-tissue defects. This study investigated the long-term in vivo survival of 3D-bioprinted LAT and its proteomic signature and cellular composition. We performed proteomic and multicolour flow cytometric analyses on the lipoaspirate and 3D-bioprinted LAT constructs were transplanted into nude mice, followed by explantation after up to 150 days. LAT contained adipose-tissue-derived stem cells (ASCs), pericytes, endothelial progenitor cells (EPCs) and endothelial cells. Proteomic analysis identified 6,067 proteins, including pericyte markers, adipokines, ASC secretome proteins, proangiogenic proteins and proteins involved in adipocyte differentiation and developmental morphogenic signalling, as well as proteins not previously described in human subcutaneous fat. 3D-bioprinted LAT survived for 150 days in vivo with preservation of the construct shape and size. Furthermore, we identified human blood vessels after 30 and 150 days in vivo, indicating angiogenesis from capillaries. These results showed that LAT has a favourable proteomic signature, contains ASCs, EPCs and blood vessels that survive 3D bioprinting and can potentially facilitate angiogenesis and successful autologous fat grafting in soft-tissue reconstruction.